FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight The FDA's Pharmacy Compounding Advisory Committee recently voted 8 6 with one abstention to recommend four peptides for inclusion on the 503A Bulks List.
The decision has sent shockwaves through the pharmaceutical and biotech industries, with investors taking note. Hims & Hers Health Inc. 's stock jumped over 3% in response to the news, but it's far from a done deal.
The FDA still needs to weigh in on the matter, and given initial opposition from agency staff scientists, there's no guarantee these peptides will gain regulatory approval.